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Abstract
Background: Over-activated microglia and chronic neuroinflammation contribute to dopaminergic neuron
degeneration and progression of Parkinson’s disease (PD). Leucine-rich repeat kinase 2 (LRRK2), a kinase mutated
in autosomal dominantly inherited and sporadic PD cases, is highly expressed in immune cells, in which it
regulates inflammation through a yet unclear mechanism.
Methods: Here, using pharmacological inhibition and cultured Lrrk2−/− primary microglia cells, we validated LRRK2 as
a positive modulator of inflammation and we investigated its specific function in microglia cells.
Results: Inhibition or genetic deletion of LRRK2 causes reduction of interleukin-1β and cyclooxygenase-2 expression
upon lipopolysaccharide-mediated inflammation. LRRK2 also takes part of the signaling trigged by α-synuclein fibrils,
which culminates in induction of inflammatory mediators. At the molecular level, loss of LRRK2 or inhibition of its
kinase activity results in increased phosphorylation of nuclear factor kappa-B (NF-κB) inhibitory subunit p50 at S337,
a protein kinase A (PKA)-specific phosphorylation site, with consequent accumulation of p50 in the nucleus.
Conclusions: Taken together, these findings point to a role of LRRK2 in microglia activation and sustainment of
neuroinflammation and in controlling of NF-κB p50 inhibitory signaling. Understanding the molecular pathways
coordinated by LRRK2 in activated microglia cells after pathological stimuli such us fibrillar α-synuclein holds the
potential to provide novel targets for PD therapeutics.
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Background
Mutations in the leucine-rich repeat kinase 2 (Lrrk2) gene
cause late-onset, autosomal dominant Parkinson’s disease
(PD) with clinical and pathological phenotypes almost
indistinguishable from those of idiopathic disease [1, 2].
Lrrk2 encodes a large multidomain protein belonging to
the ROCO (Ras Of COmplex) family of proteins, which is
characterized by the presence of a catalytic domain com-
prising a ROC (Ras Of Complex proteins)/GTPase, a
COR (C-terminus of ROC) and a serine threonine kinase
domain, and a number of repeat sequences important for
protein-protein or protein-membrane interactions at both
the N- and C-terminals [1, 3]. Among all identified Lrrk2
pathological mutations, G2019S, located in the kinase
domain, is by far the most frequent in both familial and
apparently sporadic PD cases [4]. The G2019S mutation
has attracted much attention as it robustly enhances
LRRK2 kinase activity in vitro [5, 6] and in vivo [7], and
this activity has been reported to be toxic to neuronal cells
[5, 8]. Of interest, Sheng and colleagues observed that
additional pathological mutations, other than G2019S,
display increased kinase activity by monitoring LRRK2
autophosphorylation at S1292 [7], supporting the notion
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that the pathogenic effects of LRRK2 might be mediated
by an augmented kinase activity.
LRRK2 has been linked to several pathways in neuronal
cells, including vesicular trafficking [9, 10], cytoskeletal
dynamics [11–13], mitochondrial functions [14, 15],
apoptosis [16], and autophagy process [17, 18]. However,
how LRRK2 pathogenic mutants contribute to neuro-
degeneration in PD remains elusive. Multiple studies
reported that LRRK2 is more expressed in immune cells,
especially in B cells, monocytes, macrophages, and micro-
glia compared to T cells [19]. Furthermore, it has been
found that cultured microglia display ~three- to fourfold
more LRRK2 basal expression than neuronal cells [20],
implying a crucial role of LRRK2 in these cells. Thus, one
hypothesis is that pathological LRRK2 activity in microglia
cells may impact neuronal functions as secondary event.
In support of a crucial role of this protein in the immune
system, genome-wide association studies identified Lrrk2
as one of the susceptibility genes for leprosy and Crohn’s
disease [21, 22], two illnesses with a significant inflam-
matory component. Coherently, analysis of inflammed
colonic tissue from Crohn’s disease patients revealed in-
creased levels of LRRK2 expression [19]. At the molecular
level, LRRK2 has been shown to negatively control the
nuclear transcription factor NFAT in bone marrow-
derived macrophages and the inflammatory response [23].
Instead, in cultured microglia cells, the kinase was sug-
gested to regulate the activity of the transcription factor
nuclear factor kappa-B (NF-κB) through a yet unknown
mechanism [24]. NF-κB transcription factor signaling is
one of the main regulators of cyclooxygenase-2 (COX-2),
interleukin-1β (IL-1β), and other pro-inflammatory medi-
ators during inflammation [25]. The most abundant form
of NF-κB is the heterodimer composed by p65 and p50
subunit [26]. Specifically, p50 is generated from the pro-
teolytic processing of the precursor p105, it lacks the tran-
scription activation domain, and it forms homodimers
with no ability to activate gene expression [27]. In un-
stimulated cells, p50 is detected in the nucleus where it is
primarily present as homodimer able to bind DNA and re-
press NF-κB-dependent gene expression [27–29]. In the
canonical pathway, NF-κB p65 bound to IκBs inhibitory
proteins is phosphorylated at S536 by the IKK complex
upon an inflammatory stimulus. This results in IκBs pro-
teasomal degradation and release of NF-κB p65:p50
dimers that enter the nucleus and activate transcription
of target genes [30]. Thus, the activated p65:p50 hetero-
dimers are able to bind DNA and induce gene expres-
sion by displacing the p50:p50 homodimers [27].
In this study, using the GSK2578215A (GSK) inhibitor
and cultured Lrrk2−/− primary microglia cells, we
validated LRRK2 as a positive modulator of inflamma-
tion in microglia cells. We showed that LRRK2 takes
part of the signaling trigged by α-synuclein (α-syn)
fibrils, which culminates in microglia activation and
induction of inflammatory IL-1β cytokine. We further
demonstrated that Lrrk2−/− primary microglia, under
unstimulated conditions, display increased levels of
nuclear and S337 phosphorylated NF-κB p50 compared to
Lrrk2+/+ cells. We validated the increased level of p50
phosphorylation also in BV2 cells upon LRRK2 pharma-
cological inhibition and ex vivo using Lrrk2 knock-out
mouse brain lysates. Overall, our data suggest that LRRK2
kinase activity may control microglial inflammation by
regulating protein kinase A (PKA)-mediated NF-κB p50
phosphorylation, which is crucial for binding and re-
pression of NF-κB target genes. Given that chronic
neuroinflammation is recognized to contribute to PD
pathogenesis, understanding the specific function(s) of
LRRK2 activity in microglia cells and during inflammation
may disclose novel pathways for therapeutic intervention.
Methods
Cell cultures
BV2 cells were cultured in RPMI-40 medium (Sigma-
Aldrich) supplemented with 10 % fetal bovine serum (FBS)
(Life technologies), 2 mM glutamine (Sigma-Aldrich), and
penicillin and streptomycin (Life technologies) and main-
tained at 37 °C in a 5 % CO2 controlled atmosphere.
Primary microglia cell cultures
All animal procedures were performed following the guide-
lines issued by the European Community Council Directive
2010/63/UE and approved by the Ethics Committee of the
University of Padova (Project ID: 46/2012). Microglia cells
were derived from postnatal days 1–4 (P1-P4) Lrrk2+/+ and
Lrrk2−/− mouse brains (C57BL/6J). Cerebral cortices were
mechanically dissociated in cold HBSS (Sigma-Aldrich),
then cellular suspension was allowed to settle for 5 min,
and the top fraction was collected, centrifuged for 5 min at
1000 g, and re-suspended in DMEM-F12, supplemented
with 10 % FBS, 2 mM glutamine, 2 mM sodium pyruvate
(Sigma-Aldrich), penicillin, and streptomycin. Cell suspen-
sion obtained from the three brains was plated on poly-L-
lysine (0.1 mg/ml, Sigma-Aldrich) coated T-75 flask. After
4 days, the medium was replaced, and the mixed glial cul-
ture was maintained until day 14. At 14 days, microglia
cells were isolated from the mixed culture by shaking 4 h
at 160 rpm, and the purity of the obtained culture was
verified by double immunofluorescence with mouse anti-
CD11b (Cell signaling) for microglia cells and with rabbit
anti-GFAP (DAKO) for astrocytes. The primary microglia
yield was ~5 × 105 cells/flask, and the amount of astrocyte
contaminants was negligible.
Production and aggregation of recombinant α-syn
Human α-syn fibrils were generated from recombinant
α-syn produced by a lipid A mutant of Escherichia coli,
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BL21(DE3) with strongly reduced endotoxicity [31].
After purification, α-syn was incubated for 15 days to
induce aggregation and quantified as previously re-
ported [32].
Compounds and treatments
During treatments, BV2 and primary microglia cells
were cultured in medium containing 1 % FBS. Inflam-
mation was induced using 50 EU/ml lipopolysaccharide
(LPS) from E. coli O111:B4 (Sigma-Aldrich, L4391,
potency 500,000 EU/mg) suspended in phosphate-
buffered saline (PBS) or α-syn fibrils at 25 μM (monomer
concentration before fibrillation). PBS (Life technologies)
or α-syn monomer at 25 nM were used as control. To
evaluate the effect of LRRK2 on pro-inflammatory pro-
teins (BV2 and primary microglia cells) and on mRNAs
(BV2 cells), LPS treatment was maintained for 5 h,
whereas to evaluate the effect of LRRK2 on mRNAs and
LPS molecular signaling (primary microglia and BV2
cells), LPS treatment was maintained for 90 min. LRRK2
inhibitors GSK and IN-1 (Tocris Bioscience) were used at
2 and 1 μM, respectively, and maintained in the medium
for all the time of inflammatory treatment. Forskolin
(Sigma-Aldrich) and PKI (Tocris Bioscience) were used at
30 and 20 μM, respectively, for 90 min.
Cells and brain lysis and western blotting
Cells washed with PBS and mouse brains after dissection
were solubilized with lysis buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 1 mM EDTA, 2.5 mM sodium pyro-
phosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4)
supplemented with 1 % Triton X-100 (Sigma-Aldrich) and
protease inhibitor cocktail (Sigma-Aldrich) and then
cleared at 14,000 g at 4 °C for 30 min. Protein concen-
trations were determined using the BCA protein con-
centration assay as manufacturer’s instructions (Thermo
Scientific). Subsequently, proteins were separated by elec-
trophoresis onto 4–20 % SDS-PAGE gels and then trans-
ferred onto Immobilon-P membrane. Membranes were
incubated 1 h at room temperature (RT) with the fol-
lowing antibodies: rabbit anti-LRRK2 MJFF2 (1:1000,
Abcam), rabbit anti-IL1β (1:1000, Santa Cruz), rabbit
anti-COX-2 (1:2000, Cayman Chemical), mouse anti-
GAPDH (1:2000, Millipore), mouse anti-β-tubulin
(1:3000, Sigma-Aldrich), mouse α-actin (1:3000, Sigma-
Aldrich), rabbit anti-p65 total (1:2000, Cell signaling),
rabbit anti-phospho serine 536 p65 (1:1000, Cell signal-
ing), rabbit anti-p105/p50 (1:2000, Cell signaling), and
rabbit anti-phospho serine 337 p50 (1:1000, Santa
Cruz). Subsequently, membranes were incubated 1 h at
RT with HRP-conjugated secondary antibodies (Sigma-
Aldrich) and finally incubated with ECL western blot
substrate (Thermo Scientific).
RNA extraction, retro-transcription and
semi-quantitative PCR
BV2 and primary microglia cells were collected with TRI-
zol (Life Technologies) and incubated 15 min at RT. After
adding chloroform, cells were incubated for 15 min and
then centrifuged at 12,000 g for 15 min at 4 °C. Subse-
quently, to precipitate RNA, 100 % isopropanol was added
to the aqueous phase, incubated 10 min at RT, and centri-
fuged at 12,000 g for 15 min at 4 °C. The RNA pellet was
washed with 75 % ethanol, air-dried for 30 min, and then
resuspended in RNAse-free water. Retro-transcription was
carried out using ImProm-II Reverse Transcriptase as
manufacturer’s instructions (Promega). Briefly, 1 μg RNA
was mixed with 1 μl of 500 ng/μl random primers
(Promega) and incubated 70 °C for 5 min and then 4 °C
for 5 min. Then, reverse transcription mix was prepared
with 5X reaction buffer (Promega), 1 μl of 100 μM dNTPs,
1 μl of 40 U/μl RNasin (Promega), and 1 μl ImProm-II RT
(160 u/μl) in a final volume of 20 μl and incubated at
25 °C for 5 min and 42 °C for 1 h, and finally, the
enzyme was inactivated at 70 °C for 15 min.
To analyze RNA expression, semi-quantitative PCRs
were carried out using the following primer sequences
(IL-1β FOR 5′-GGCAACTGTTCCTGAACTCAACTG-
3′ and REV 5′-CCATTGAGGTGGAGAGCTTTCA-3′;
COX-2 FOR 5′-TCAAAAGAAGTGCTGGAAAAGGT-
3′ and REV 5′-GATCATCTCTACCTGAGTGTCT-3′;
GAPDH FOR 5′-GAGAGTGTTTCCTCGTCCCG-3′
and REV 5′-ACTGTGCCGTTGAATTTGCC-3′). For
PCR reaction, we used 20 ng of cDNA and 25 amplifica-
tion cycles (linear phase of the PCR reaction) for each
gene analyzed.
Immunofluorescence and confocal imaging
Cells were washed once with PBS and fixed using 4 %
paraformaldehyde for 20 min. Then, cells were per-
meabilized with 0.3 % Triton X-100 in PBS for 5 min and
saturated with blocking solution containing 5 % FBS and
0.3 % Triton X-100 in PBS for 30 min at RT. Primary
antibodies CD11b (1:100), GFAP (1:100), and p105/p50
(1:100) diluted in blocking solution were incubated 1 h at
RT. After several washes, the cells were incubated 1 h at
RT with secondary antibodies Alexa-fluor 488 and Alexa-
fluor 546 (1:200, Life Technologies), and after repeated
washes, the cells were mounted using Mowiol reagent
containing Hoechst (Roche). Images were acquired with a
Leica TCS SP5 confocal microscope using Zeiss 63X ob-
jective. Quantifications of nuclear p50 were performed
using ImageJ software. In detail, the mean of fluorescence
intensity was calculated as p50 nuclear fluorescence inten-
sity divided by the nuclear area and expressed as nuclear
intensity/μm2. Quantification was performed in blind, and
at least ninety cells were randomly chosen in four inde-
pendent experiments per genotype.
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TEM
α-Syn fibrils resuspended in PBS were absorbed onto a
carbon-coated copper grid and were then negative stained
with 0.05 % uranyl acetate solution. Transmission electron
microscopy (TEM) micrographs were taken with a FEI
Tecnai G2 12 electron microscope operating at 100 kV.
Statistical analysis
All quantitative data are expressed as mean ± SEM and
represent at least three independent sets of experiments.
Statistical significance of differences between two groups
was assessed by unpaired t test, while for multiple com-
parisons by one-way ANOVA with Tukey’s post- hoc
test. Cumulative frequency distributions were compared
with a Kolmogorov-Smirnov test. Data were analyzed
using Prism (GraphPad).
Results
LRRK2 pharmacological inhibition attenuates
pro-inflammatory mediators at protein and mRNA levels
after LPS-mediated inflammation
Pharmacological inhibition of LRRK2 attenuates inflamma-
tory response in microglia cells after LPS or HIV-1 Tat pro-
tein pathological stimuli, indicating that LRRK2 may
control inflammation through its kinase activity [33, 34].
However, LRRK2 inhibitors have been shown to have off-
target effects [35, 36], highlighting the need of using
multiple pharmacological tools in conjunction with genetic
approaches to study LRRK2 functions. To this aim, we vali-
dated the role of LRRK2 kinase activity after LPS-mediated
inflammation using LRRK2-IN-1 [37] and GSK2578215A
(hereafter GSK), a selective LRRK2 inhibitor [38].
To assess whether LRRK2 kinase activity controls the
induction of pro-inflammatory mediators, we treated BV2
cells with LPS for 5 h in the presence of LRRK2 inhibition.
We extended the incubation time of LRRK2 inhibitor to
that of LPS since pro-inflammatory mediators can be gen-
erated throughout the LPS treatment time. In agreement
with previous reports [33, 34], IN-1 decreases the inflam-
matory response as revealed by reduction of COX-2 and
IL-1β precursor (hereafter IL-1β) after LPS priming
(Fig. 1a, b). Importantly, we confirmed these findings with
GSK inhibitor. As shown in the Fig. 1, LPS-mediated in-
crement of COX-2 and IL-1β cytokine is attenuated in the
presence of GSK, at translation (Fig. 1c, d) and transcrip-
tion levels (Fig. 1e, f ). Of note, LRRK2 steady state levels
were unchanged upon LPS treatment (Fig. 1g, h). Taken
together, these results indicate that LRRK2 kinase activity
modulates the inflammatory response in microglia cells.
Lrrk2−/− primary microglia cells exhibit attenuated
pro-inflammatory mediators after LPS priming
To validate the contribution of LRRK2 in microglia during
inflammation, we investigated the response of cultured
Lrrk2+/+ and Lrrk2−/− primary microglia cells to LPS prim-
ing. Primary microglia cells were isolated from Lrrk2+/+
and Lrrk2−/− mice. The amount of astrocyte contaminants
was negligible, as showed by immunocytochemistry for
CD11b-positive microglia cells and GFAP-positive cells
(Fig. 2a). Lrrk2 genetic deletion was confirmed by
immunoblotting in Lrrk2+/+ and Lrrk2−/− microglia cells
(Fig. 2b). Similar to BV2 cells, primary microglia cells
treated with LPS for 5 h did not exhibit a significant
change in LRRK2 expression (Fig. 2b, c). However, when
we analyzed the levels of LPS-mediated pro-inflammatory
mediators in Lrrk2+/+ and Lrrk2−/− microglia cells, we
found that Lrrk2−/− microglia cells displayed ~55 %
reduction of IL-1β mRNA expression (Fig. 2d, e) and a re-
duction of ~80 % of COX-2 and 50 % of IL-1β protein
levels, respectively, compared to Lrrk2+/+ cells (Fig. 2f, g).
All together, these findings indicate that LRRK2 modulates
inflammation acting upstream of pro-inflammatory
mRNA transcription.
Lrrk2−/− primary microglia cells exhibit attenuated
inflammatory response after priming with α-syn fibrils
Multiple lines of evidence suggest that aggregated forms
of α-syn released from dying neurons can activate
microglia [39, 40]. Thus, we asked whether LRRK2
participates in the inflammatory response mediated by
α-syn aggregated forms. To this end, we generated α-syn
fibrils from recombinant α-syn produced using bacteria
with reduced endotoxicity (Fig. 3a). α-Syn monomers
were incubated for 15 days to induce aggregation, and
fibrils formation was validated by both Thioflavin assay
and TEM imaging (Fig 3b, c).
In analogy to the experiments with LPS, α-syn
treatments were performed in 1 % FBS containing
medium, a condition we observed to induce the max-
imal response in terms of IL-1β and COX-2 induction.
Inflammation was triggered using 25 μM α-syn fibrils
(expressed as initial concentration of monomer before
fibrillation), and α-syn monomer at 25 nM was used as
control. Considering that one fibril is estimated to
contain ~10.000 monomers [41], 25 nM of monomeric
α-syn corresponds to a ~10× molar excess of α-syn
fibrils (2.5 nM). We treated Lrrk2+/+ microglia cells
with 25 μM α-syn fibrils for 6 and 20 h and found that
α-syn fibrils are able to induce the expression of pro-
inflammatory IL-1β protein only after 20 h of treatment
(Fig. 3d). Interestingly, when we examined IL-1β con-
tent in Lrrk2−/− microglia cells, we observed a marked
decreased of protein levels compared to Lrrk2+/+
microglia cells (Fig. 3e, f ), indicating that LRRK2 is part
of the molecular pathway trigged by α-syn fibrils, which
culminates in microglia activation. Of note, LRRK2
steady state levels did not change upon treatment with
α-syn fibrils for 20 h (Fig. 3g, h).
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Fig. 1 (See legend on next page.)
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LRRK2 does not influence p65 phosphorylation and p50
maturation upon LPS priming
Having established that LRRK2 is a positive mediator of
microglial inflammation triggered by LPS and, more im-
portantly, fibrillar α-syn, we next asked which molecular
mechanism might govern this process. Starting from the
observation that (1) LRRK2 has been reported to
influence NF-κB transcription activity [24], (2) both LPS
[42] and aggregated α-syn [43] activate NF-κB signaling
to induce inflammation, and (3) Lrrk2−/− microglia cells
display decreased pro-inflammatory mediators upstream
of mRNA transcription (Fig. 2), we investigated whether
cultured Lrrk2−/− microglia cells exhibit alterations of
the NF-κB pathway after an inflammatory stimulus.
First, we asked whether LRRK2 influences p65 signaling
after LPS-mediated inflammation. Both Lrrk2+/+ and
Lrrk2−/− microglia cells primed with LPS for 90 min
showed a significant increase of p65 phosphorylation at
S536, a readout of p65 activation [44], with no difference
between the two genotypes (Fig. 4a, b), indicating that
LRRK2 does not appear to influence p65 activation and
the related signaling. Second, we analyzed the expression
levels of both p50 and its p105 precursor in Lrrk2+/+
and Lrrk2−/− primary microglia cells. Treatment with
LPS (90 min) induced a reduction of p105 precursor and a
trend of increment of the p50 mature form, as expected,
with no difference between Lrrk2+/+ and Lrrk2−/− primary
microglia cells (Fig. 4c–e), suggesting that LRRK2 may not
intervene in the maturation of p50.
Lrrk2−/− primary microglia cells exhibit increased levels of
phosphorylated and nuclear NF-κB p50
Starting from the observation that DNA binding by
p50:p50 homodimer is increased in BV2 cells when
LRRK2 is knocked-down [24], we next asked whether
LRRK2 impacts the NF-κB p50 inhibitory signaling. To
this end, we analyzed the levels of p50 phosphorylation
at S337 (P-p50) in Lrrk2+/+ and Lrrk2−/− cells. Con-
stitutive phosphorylation of S337 by PKA increases p50
affinity to DNA [45] maintaining stable negative regula-
tion of NF-κB gene expression in the absence of
extracellular stimulation [46]. Since LRRK2 was recently
shown to negatively regulate PKA activation [47], we
investigated whether S337 phosphorylation was altered
in cultured Lrrk2−/− microglia. As shown in (Fig. 5a, b),
Lrrk2−/− microglia cells exhibit ~65 % increase of P-p50
phosphorylation compared to Lrrk2+/+ microglia. In
support of these findings, p50 phosphorylation is also
enhanced in Lrrk2−/− mouse brains (Fig. 5c, d) and in
BV2 cells upon GSK pharmacological inhibition (Fig. 5e, f),
suggesting that LRRK2 might modulate p50 affinity to
DNA and the consequent repression of NF-κB-dependent
gene transcription.
In contrast to p65:p50 heterodimer whose nuclear
translocation is tightly regulated in presence of extracel-
lular stimuli [48], p50:p50 homodimer is constitutively
imported into the nucleus where it represses gene tran-
scription [29]. Given that S337 phosphorylation controls
p50:p50 binding to DNA [45], we then investigated
whether the increased P-p50 observed in Lrrk2−/− micro-
glia correlates with an increased nuclear content of p50.
To this aim, we quantified p50 nuclear fluorescence in
unstimulated microglia cells. As shown in (Fig. 5g, h),
Lrrk2−/− microglia exhibit a higher proportion of nuclear
p50 compared to Lrrk2+/+ cells. The cumulative fre-
quency distribution analysis reveals that Lrrk2−/− cells
display p50 nuclear fluorescence consistently shifted to-
ward higher intensity values with respect to Lrrk2+/+
cells (Fig. 5i), indicating a homogeneous increased of
nuclear p50 in Lrrk2−/− cells.
To verify that phosphorylation of p50 at S337 is a
bona fide PKA phosphorylation site, we treated BV2
cells with forskolin, an activator of adenylate cyclase,
and PKI, a specific PKA inhibitor [49]. Compared to
untreated cells, forskolin induces ~twofold increment of
p50 phosphorylation, which is attenuated by ~onefold in
the presence of PKI (Fig. 5j, k).
Taken together, our results suggest that LRRK2 modu-
lates NF-κB p50 affinity to DNA through control of NF-κB
p50 phosphorylation and consequent nuclear localization
and suggest that the reduced inflammatory response of
cells with LRRK2 pharmacological inhibition or deficiency
(See figure on previous page.)
Fig. 1 LRRK2 kinase inhibition attenuates inflammation in BV2 cells. a BV2 cell lysates treated with LPS, LPS and IN-1, and IN-1 alone or DMSO as
control were subjected to immunoblotting using COX-2 and IL-1β antibodies. b Quantification of COX-2 and IL-1β are normalized for α-actin
protein. Data are representative of three independent experiments (bars represent the mean ± SEM; one-way ANOVA comparing all groups,
Tukey’s multiple comparison post hoc test; ***p < 0.001). c BV2 cell lysates treated with LPS, LPS and GSK, and GSK alone or DMSO as control
were subjected to immunoblotting using COX-2 and IL-1β antibodies. d Quantification of COX-2 and IL-1β are normalized for β-tubulin. Data are
representative of three independent experiments (bars represent the mean ± SEM; one-way ANOVA comparing all groups, Tukey’s multiple
comparison post hoc test; **p < 0.01 and ***p < 0.001). e BV2 cell lysates treated with LPS, LPS and GSK, and GSK alone or DMSO as control were
subjected to semi-quantitative PCRs. f Quantification of COX-2 and IL-1β mRNAs are normalized for GAPDH. Data are representative of three
independent experiments (bars represent the mean ± SEM; one-way ANOVA comparing all groups, Tukey’s multiple comparison post hoc test;
*p < 0.05, **p < 0.01 and ***p < 0.001). g BV2 cell lysates treated with LPS and DMSO as control were subjected to immunoblotting using LRRK2
and β-tubulin antibodies. h Quantification of LRRK2 protein is normalized for β-tubulin. Data are representative of six independent experiments
(bars represent the mean ± SEM; unpaired t test)
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may be due to an enhanced phosphorylation of NF-κB p50
inhibitory subunit bound to DNA (Fig. 6).
Discussion
Over-activated microglia and chronic neuroinflammation
may contribute to dopaminergic neuron degeneration and
progression of PD [50]. While growing evidence supports
a role of LRRK2 in activation of microglia cells [51, 52], its
precise function in these cells remains poorly understood.
In this study, using pharmacological inhibition in conjunc-
tion with Lrrk2 knock-out cells, we provide evidence for a
novel role of LRRK2 in the microglia.
LRRK2 kinase inhibition with IN-1 or Sunitinib has
been previously reported to reduce transcription of
Fig. 2 Lrrk2−/− primary microglia cells exhibit attenuated inflammation. a Lrrk2+/+ and Lrrk2−/− primary microglia culture purity. Representative images
of Lrrk2+/+ and Lrrk2−/− primary microglia culture stained for microglial CD11b (green), astrocytic GFAP (red), and nuclei with Hoechst (blue). Scale bar
25 μm. b Lrrk2+/+ and Lrrk2−/− microglia lysates treated with LPS or PBS as control were subjected to immunoblotting using LRRK2 and β-tubulin
antibodies. c Quantification of LRRK2 protein is normalized for β-tubulin. Data are representative of three independent experiments (bars represent the
mean ± SEM; unpaired t test). d Lrrk2+/+ and Lrrk2−/− microglia lysates treated with LPS or PBS as control were subjected to semi-quantitative PCR.
e Quantification of LPS-mediated IL-1β mRNA is normalized for GAPDH. Data are representative of three independent experiments (bars represent the
mean ± SEM; unpaired t test; *p < 0.05). f Lrrk2+/+ and Lrrk2−/− microglia lysates treated with LPS or PBS as control were subjected to immunoblotting
using COX-2 and IL-1β antibodies. g Quantification of LPS-mediated COX-2 and IL-1β are normalized for β-tubulin. Data are representative of three
independent experiments (bars represent the mean ± SEM; unpaired t test; *p < 0.05, **p < 0.01)
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inflammatory mRNAs induced by pathological condi-
tions [33, 34, 53]. However, these inhibitors have shown
significant off-target effects [35, 36], calling for inde-
pendent evaluations of LRRK2 immunological function
in the microglia. Here, we investigated the role of
LRRK2 after LPS-mediated inflammation using the
selective GSK2578215A inhibitor [38] and cultured
Lrrk2−/− primary microglia cells. We demonstrated that
both BV2 treated with GSK and Lrrk2−/−microglia cells
exhibit significant attenuation of inflammation at both
transcription and translation levels, supporting the
notion that the kinase activity of LRRK2 acts upstream
of inflammatory mRNA transcription after LPS priming.
Neuroinflammation is a well-described condition in
parkinsonian brains [54]. Dopaminergic neurons of the
substantia nigra pars compacta, which are preferentially
depleted during disease, are surrounded by an abnor-
mally high concentration of microglia cells compared to
other brain regions [55], making these neurons more
susceptible to an inflammatory insult. Among the en-
dogenous agents that might be competent of activating
microglia cells, α-syn is a top candidate. It has been
recently shown that α-syn induces microglia activation
by engaging the heterodimer TLR1/2 (Toll-like receptors
1/2), which triggers nuclear translocation and activation
of NF-κB [43]. Additional studies in vitro [40, 56] and in
vivo [57] reported an increased expression of TLR2 and
4, supporting the notion that α-syn aggregated forms
switch on microglia through TLRs. Thus, one possibility
is that α-syn released from dying dopaminergic neurons
locally activates the abundant microglia through the
TLR/NF-κB pathway. This causes the release of pro-
inflammatory cytokines, which in turn may signal back
to neurons, initiating a vicious circle. In this scenario,
LRRK2, which is a positive modulator of neuroinflam-
mation, could mediate and contribute to α-syn-
dependent microglia activation and neuroinflammation.
To test this hypothesis, we asked whether LRRK2 is able
to modulate the inflammatory response mediated by
α-syn. Our data demonstrate that Lrrk2−/− microglia
exhibit reduced levels of IL-1β cytokine when exposed to
α-syn fibrils compared to Lrrk2+/+ cells. In line with our
findings, Lrrk2−/− rats exhibit a reduced fraction of acti-
vated microglia and are more resistant to dopaminergic
neurodegeneration after injection of rAAV2/1–α-syn in
the substantia nigra compared to wild-type rats [58]. Of
note, pathological or inhibited LRRK2 activity in microglia
cells augments or reduces neuronal toxicity, respectively,
supporting the notion that neurodegeneration might be
triggered or amplified by LRRK2-dependent neuroinflam-
mation [33, 59]. Thus, it is tempting to speculate that
LRRK2 activity contributes to sustainment of neuroinflam-
mation and that pharmacological inhibition treatments
may be effective at attenuating chronic neuroinflammation
Fig. 3 Lrrk2−/− primary microglia cells exhibit attenuated inflammation after α-syn fibrils priming. a After purification, α-syn was subjected to
reverse phase HPLC chromatography. α-syn aggregation and fibrils formation were validated by Thioflavin assay (b) and TEM imaging (c). Scale
bar 100 nm. d Lrrk2+/+ microglia lysates treated with 25 μM α-syn fibrils (concentration before fibrillation) or 25 nM α-syn monomer as control
for 6 and 20 h were subjected to immunoblotting using IL-1β antibody. e Lrrk2+/+ and Lrrk2−/− microglia lysates treated with 25 μM α-syn fibrils
(concentration before fibrillation) or 25 nM α-syn monomer as control were subjected to immunoblotting using IL-1β antibody. f Quantification
of α-syn fibrils-mediated IL-1β expression is normalized for β-tubulin. Data are representative of four independent experiments (bars represent the
mean ± SEM; unpaired t test; **p < 0.01). g Lrrk2+/+ microglia lysates treated with 25 μM α-syn fibrils (concentration before fibrillation) or 25 nM
α-syn monomer as control for 20 h were subjected to immunoblotting using LRRK2 antibody. h Quantification of LRRK2 expression is normalized
for β-tubulin. Data are representative of three independent experiments (bars represent the mean ± SEM)
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and neurodegeneration in PD patients. In this context,
several groups intensely worked to identify LRRK2
inhibitors with good physiochemical and pharmacokinetic
properties, selectivity and blood-brain barrier permeability,
against both kinase [60–63] and GTPase activities [64].
While LRRK2 inhibition has been proven to be effective at
reducing pathological LRRK2 phenotypes [65], other
studies showed that Lrrk2 knock-out mice or non-human
primates treated with chronic doses of LRRK2 inhibitors
exhibit side effects and morphologic changes in peripheral
tissue [66, 67]. Thus, additional investigations are neces-
sary to determine the appropriate pharmacological doses
to switch off the enhanced pathological kinase function
preserving LRRK2 physiological activity.
Of note, few studies showed that stimulation of im-
mune cells induces LRRK2 expression [34, 59, 68]. Here,
we found that cultured microglia cells treated with LPS
for 5 h or α-syn fibrils for 20 h did not exhibit a sig-
nificant increase in LRRK2 protein expression, possibly
indicating that LRRK2 behaves differently under distinct
stimulation conditions and/or immune cell types.
We also provided mechanistic insights into LRRK2
modulation of microglial inflammation. Given that NF-κB
transcription activity has been reported to be affected in
BV2 cells with LRRK2 knock-down after LPS priming [24]
and that both LPS [42] and aggregated α-syn forms [43]
activate NF-κB signaling to induce inflammation, we
investigated whether Lrrk2−/− and inhibited microglia cells
exhibit alterations in the NF-κB pathway. We focused on
the canonical NF-κB pathway, the p65:p50 signaling, and
found that both p50 phosphorylated at S337 and its nu-
clear localization are enhanced in cultured Lrrk2−/−micro-
glia under unstimulated conditions. We demonstrated this
LRRK2-mediated effect on P-p50 also in BV2 cells with
LRRK2 kinase inhibition and ex vivo using 12-month old
Lrrk2−/− mouse brains. It has been previously reported
that p50 phosphorylation at S337 by PKA possesses higher
affinity to DNA [45] and represses NF-κB target gene in
absence of extracellular stimuli [46]. Following stimula-
tion, p50:p65 heterodimers translocate into the nucleus,
compete, and displace DNA-bound p50:p50 to initiate
mRNAs transcription [27]. Our results suggest that the
reduced inflammatory response of cells with LRRK2
pharmacological inhibition or deficiency may be mediated
by the excessive phosphorylation of NF-κB inhibitory
p50 subunit. We propose that an abnormally higher
Fig. 4 LRRK2 does not influence p65 phosphorylation and p50 maturation upon LPS priming. a Lrrk2+/+ and Lrrk2−/− microglia lysates treated
with LPS or PBS as control were subjected to immunoblotting using NF-κB P-p65 and p65 antibodies. b Quantification of P-p65 is normalized for
p65 total protein. Data are representative of three independent experiments (bars represent the mean ± SEM; one-way ANOVA comparing all
groups, Tukey’s multiple comparison post-hoc test). c Lrrk2+/+ and Lrrk2−/− microglia lysates treated with LPS or PBS as control were subjected to
immunoblotting using NF-κB p105/p50 antibody. Quantification of p105 (d) and p50 (e) proteins are normalized for GAPDH. Data are representative of
three independent experiments, respectively, (bars represent the mean ± SEM; one-way ANOVA comparing all groups, Tukey’s multiple comparison
post hoc test)
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proportion of P-p50 in the nucleus of Lrrk2−/− or
LRRK2-inhibited cells hampers p65:p50 binding to
DNA and activation of gene transcription (Fig. 6). Co-
herently, with the hypothesis proposed here, Kim and
colleagues reported that immortalized BV2 microglia
with LRRK2 knock-down display more p50:p50 bound
to DNA compared to wild-type cells in control con-
dition and also after LPS treatment [24]. Taken the
Fig. 5 Lrrk2−/− primary microglia cells reported increased levels of phosphorylated and nuclear NF-κB p50 subunit under unstimulated conditions.
a Lrrk2+/+ and Lrrk2−/− microglia lysates were subjected to immunoblotting using NF-κB P-p50 and p50 total antibodies. b Quantification of P-p50
subunit is normalized for p50 total protein. Data are representative of three independent experiments (bars represent the mean ± SEM; unpaired
t test; **p > 0.01). c Lrrk2+/+ and Lrrk2−/− brain lysates were subjected to immunoblotting using NF-κB P-p50 and p50 total antibodies. d Quantification
of P-p50 subunit is normalized for p50 total protein. Data are representative of three independent experiments (bars represent the mean ± SEM;
unpaired t test; *p > 0.05). e BV2 cell lysates treated with GSK or DMSO as control were subjected to immunoblotting using NF-κB P-p50 and p50 total
antibodies. f Quantification of P-p50 subunit is normalized for p50 total protein. Data are representative of three independent experiments (bars
represent the mean ± SEM; unpaired t test; *p > 0.05). g Representative images of unstimulated Lrrk2+/+ and Lrrk2−/− microglia cells stained for NF-κB
p50 (red) and nuclei with Hoechst (blue). Scale bar 10 μm. h Quantification of nuclear NF-κB p50 shown as mean of fluorescence intensity from four
independent experiments (~90 cells per experiment per genotype). Nuclear NF-κB p50 was calculated as nuclear fluorescence intensity divided by
the nuclear area (μm2) (bars represent the mean ± SEM; unpaired t test; *p < 0.05). i Cumulative frequency distributions of nuclear p50 in Lrrk2+/+ and
Lrrk2−/− microglia cells (n(Lrrk2+/+) = 352 and n(Lrrk2−/−) = 377; Kolmogorov-Smirnov test, p = 0.004). j BV2 cell lysates treated with forskolin or PKI were
subjected to immunoblotting using P-p50 and p50 total antibodies. k Quantification of P-p50 is normalized for p50 total protein. Data are representative
of five independent experiments (bars represent the mean ± SEM; unpaired t test; *p > 0.05, ***p > 0.001)
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results previously reported and our findings together,
LRRK2 kinase activity may modulate the induction of
pro-inflammatory mediators by a negative regulation
of PKA activity. Supporting a functional interaction
between these two proteins, LRRK2 has been recently
reported to act as a negative regulator of PKA signal-
ing [47]. Specifically, the authors proposed LRRK2 as
a novel AKAP, demonstrating that a lack of LRRK2
promoted synaptic translocation of PKA and in-
creased PKA-mediated phosphorylation of cofilin and
glutamate receptor GluR1, with consequent abnormal
synaptogenesis [47].
Conclusions
Overall, our study validates LRRK2 kinase activity as a
positive modulator of inflammation in microglia cells.
LRRK2 activity negatively regulates NF-κB p50 phos-
phorylation and nuclear translocation under physiological
conditions; this might be one molecular mechanism
underlying the reduction of NF-κB target-genes
transcription during inflammatory stimuli. This study
expands our understanding of LRRK2 function in
microglia cells and suggests that additional research
should be directed at identifying LRRK2 inhibition
doses able to reduce LRRK2 pathological activity
preserving its physiological function. Lowering LRRK2
kinase activity may allow to attenuate microglia activa-
tion and chronic neuroinflammation in PD patients.
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